Calypte Biomedical to Announce First Quarter 2003 Financial Results.Business Editors/Health/Medical Writers ALAMEDA, Calif.--(BUSINESS WIRE)--April 21, 2003 Calypte Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CALY) the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot Western blot A technique developed in 1979 that is used to confirm ELISA results. HIV antigen is purified by electrophoresis and attached by blotting to a nylon or nitrocellulose filter. supplemental test, announced it will host a conference call on Thursday, April 24, 2003 at 8:00 am Pacific, 11:00 am Eastern, to discuss its first quarter 2003 financial results. Investors in the U.S. and Canada interested in participating in the conference call may dial 800-257-1836 and reference the Calypte Biomedical call. International investors may dial 212-329-1451. Calypte recommends dialing into the call approximately 10 minutes prior to the scheduled start time. A live webcast of the conference call will be available on the investors section of the company's website at www.calypte.com. The webcast will be available until May 24, 2003. A replay will be available through May 1, 2003 by calling 800-405-2236. International callers should dial 303-590-3000 for the replay. The replay confirmation code is 536115. About Calypte Biomedical Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. Type 1 (HIV-1), sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely and other infectious diseases. Calypte's tests include the screening EIA (Electronic Industries Alliance, Arlington, VA, www.eia.org) A membership organization founded in 1924 as the Radio Manufacturing Association. It sets standards for consumer products and electronic components. and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Refer to current product package inserts for complete information on product performance characteristics. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion